Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494506 · ClinicalTrials.gov registry record · Phase 3
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 417
- Enrollment target
NCT01494506 is a Phase 3 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 417 participants.
The verdict
NCT01494506, a Phase 3 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 417 participants
- Enrollment target
Study Summary
The study is an open label, randomized phase 3 study of MM-398 with or without 5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and leucovorin in metastatic pancreatic cancer patients who have progressed on prior gemcitabine based therapy.
Interventions
- DRUG Leucovorin
- DRUG 5 Fluorouracil
- DRUG MM-398
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494506
The ClinicalTrials.gov registry entry for NCT01494506 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Leucovorin is the first listed.
NCT01494506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01494506 about?
NCT01494506 is a clinical study titled "Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer". The study is an open label, randomized phase 3 study of MM-398 with or without 5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and leucovorin in metastatic pancreatic cancer patients who have progressed on prior gemcitabine based therapy.
What is the current status of trial NCT01494506?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 417 participants. The study started on 2011-11. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01494506?
The interventions under investigation include: Leucovorin (DRUG), 5 Fluorouracil (DRUG), MM-398 (DRUG).
Who is sponsoring clinical trial NCT01494506?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.